Table 1.
Baseline demographics and clinical characteristics among patients with clear cell metastatic renal cell carcinoma who received first‐line sunitinib since 2010, stratified by IMDC prognostic risk groups
| Characteristics | Overall (n = 1,769), n (%) | IMDC prognostic risk group, n (%) | ||
|---|---|---|---|---|
| Favorable (n = 318, 18.0%) | Intermediate (n = 1,031, 58.3%) | Poor (n = 420, 23.7%) | ||
| Demographic characteristics | ||||
| Age, mean ± SD [median], years | 63.0 ± 9.9 [63.7] | 63.8 ± 9.6 [64.6] | 62.9 ± 10.2 [63.6] | 62.6 ± 9.6 [63.5] |
| Race | 1,096 | 217 | 624 | 255 |
| White | 897 (81.8) | 183 (84.3) | 505 (80.9) | 209 (82.0) |
| Nonwhite | 199 (18.2) | 34 (15.7) | 119 (19.1) | 46 (18.0) |
| Gender | 1,769 | 318 | 1,031 | 420 |
| Male | 1,309 (74.0) | 234 (73.6) | 772 (74.9) | 303 (72.1) |
| Female | 460 (26.0) | 84 (26.4) | 259 (25.1) | 117 (27.9) |
| Tumor characteristics | ||||
| Number of metastases | 1,636 | 290 | 948 | 398 |
| 1 | 1,303 (79.6) | 230 (79.3) | 729 (76.9) | 344 (86.4) |
| >1 | 333 (20.4) | 60 (20.7) | 219 (23.1) | 54 (13.6) |
| Brain metastases | 1,364 | 225 | 788 | 351 |
| Yes | 151 (11.1) | 20 (8.9) | 85 (10.8) | 46 (13.1) |
| No | 1,213 (88.9) | 205 (91.1) | 703 (89.2) | 305 (86.9) |
| Bone metastases | 1,457 | 243 | 845 | 369 |
| Yes | 536 (36.8) | 73 (30.0) | 300 (35.5) | 163 (44.2) |
| No | 921 (63.2) | 170 (70.0) | 545 (64.5) | 206 (55.8) |
| Prior treatment | ||||
| Prior nephrectomy | 1,768 | 318 | 1,031 | 419 |
| Yes | 1,501 (84.9) | 315 (99.1) | 908 (88.1) | 278 (66.3) |
| No | 267 (15.1) | 3 (0.9) | 123 (11.9) | 141 (33.7) |
| Prior IL‐2 or IFN therapy | 1,765 | 318 | 1,027 | 420 |
| Yes | 65 (3.7) | 21 (6.6) | 35 (3.4) | 9 (2.1) |
| No | 1,700 (96.3) | 297 (93.4) | 992 (96.6) | 411 (97.9) |
| Year of therapy initiation | 1,769 | 318 | 1,031 | 420 |
| 2010–2013 | 1,256 (71.0) | 226 (71.1) | 730 (70.8) | 300 (71.4) |
| 2014–2018 | 513 (29.0) | 92 (28.9) | 301 (29.2) | 120 (28.6) |
The italicized numbers represent the number of patients that had information available for each characteristic.
Abbreviations: IFN, interferon; IL‐2, interleukin 2; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium.